| Cat.No. | Name | Information |
|---|---|---|
| M8951 | WEHI-345 | WEHI-345 is a potent and selective RIPK2 inhibitor with IC50 of 0.13 μM. WEHI-345 delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation. |
| M2315 | Necrostatin-1 | Necrostatin-1 (NEC-1) is a potent inhibitor of necroptosis, with an EC50 of 490 nM in Jurkat cells. Necrostin-1 is the first identified RIPK1 inhibitor, EC50=182 nM, that reduces inflammation and inhibits colitis associated tumorigenesis. Necrostatin-1 (Nec-1) is also an inhibitor of IDO. |
| M21568 | Apostatin-1 | Apostatin-1 (Apt-1) is a new type of TRADD inhibitor. Apostatin 1 can bind to TRADD-N (KD=2.17 μM), and destroy the binding of Apostatin 1 to TRADD-C and TRAF2. Apostatin-1 regulates ubiquitination of RIPK1 and beclin 1. By activating autophagy in cells accumulated by mutated tau, α-synuclein or huntingtin, Apostatin 1 blocked apoptosis and restored homeostasis. |
| M21567 | Necrostatin-34 | Necrostatin 34 (Nec-34) is an inhibitor of RIPK1 kinase that stabilizes RIPK1 in a deactivated state by occupying specific binding pockets in the kinase domain. |
| M13556 | Necrostatin 2 | Necrostatin 2 is a potent necroptosis inhibitor. EC50 for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF-α is 0.05 μM. Necrostatin 2 is also a RIPK1 inhibitor. |
| M13405 | RIPK3-IN-1 | RIPK3-IN-1 is a RIPK3 TYPE II DFG-out inhibitor with IC50 of 9.1 nM. RIPK3-IN-1 inhibited ABL, BRAF/V599E, MAP4K3 and SRC with IC50 values of 0.37, 0.15, 0.012 and 0.075 μM, respectively. |
| M13403 | GSK840 | GSK840 is a receptor-interacting protein kinase 3(RIP3orRIPK3) inhibitor that binds to the RIP3 kinase domain with high affinity and inhibits kinase activity with an IC50 value of 0.9nM and an IC50 value of 0.3nM. |
| M13394 | GSK2593074A | GSK2593074A is a necroptosis inhibitor that inhibits RIP1 and 3. |
| M13359 | GSK963 | GSK963 is a chiral small-molecule inhibitor of RIP1 kinase (RIPK1) with an IC50 value of 29 nM. GSK963 has strong and selective inhibitory effect on the necrosis of mouse and human cells in vitro. |
| M11187 | Eclitasertib | Eclitasertib (DNL-758) is a receptor interaction protein kinase 1 (RIPK1) inhibitor, with IC50 value of <1 μΜ. |
| M11184 | GSK3145095 | GSK3145095 is a potent inhibitor of the oral activity RIP1 kinase with an IC50 of 6.3 nM with potential antitumor and immunomodulatory activity. |
| M10602 | Necrostatin 2 racemate | Necrostatin-2 racemate (also known as 7-Cl-O-Nec-1 and Nec-1s) is a potent and specific receptor-interacting protein kinase 1 (RIPK1) inhibitor lacking the IDO-targeting effect, with >1000-fold more selective for RIPK1 than for any other kinase out of 485 human kinases. |
| M9637 | RIPA-56 | RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC50 of 13 nM. |
| M9426 | GSK2983559 free acid | GSK2983559 free acid is a potent, specific and oral bioavailable receptor interacting protein 2 (RIP2) kinase inhibitor. |
| M9258 | HS-1371 | HS-1371 is a potent RIP3 kinase inhibitor with an IC50 of 20.8 nM. |
| M9074 | GSK872 | GSK872 is a receptor interacting protein kinase-3 (RIP3) inhibitor, which inhibits kinase activity with an IC50 of 1.3 nM. |
| M7942 | Necrostatin-5 | Necrostatin-5 is an inhibitor of necroptosis (non-apoptotic cell death pathway) by indirect inhibition of RIP1 kinase. |
| M5232 | GSK583 | GSK583 is a highly potent and selective inhibitor of RIP2 kinase with an IC50 of 5 nM. |
| M5209 | GSK481 | GSK481 is a highly effective, selective and specific RIPK1 inhibitor with an IC50 value of 1.3 nM, which can inhibit the phosphorylation of Ser166 in wild-type human RIPK1 (IC50 value of 2.8 nM). The IC50 value of GSK481 against U937 cells was 10 nM. |
| M58520 | RIP1/RIP3/MLKL activator 1 | RIP1/RIP3/MLKL activator 1 is a potent, blood-brain barrier permeable anti-glioma agent. RIP1/RIP3/MLKL activator 1 induces necroptosis through RIP1/RIP3/MLKL pathway. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
